Application of rational enzyme engineering in a new route to etonogestrel and levonorgestrel: carbonyl reductase bioreduction of ethyl secodione.

Women in developing countries still face enormous challenges when accessing reproductive health care. Access to voluntary family planning empowers women allowing them to complete their education and join the paid workforce. This effectively helps to end poverty, hunger and promotes good health for all. According to the United Nations (UN) organization, in 2022, an estimated 257 million women still lacked access to safe and effective family planning methods globally. One of the main barriers is the associated cost of modern contraceptive methods. Funded by the Bill & Melinda Gates Foundation, Almac Group worked on the development of a novel biocatalytic route to etonogestrel and levonorgestrel, two modern contraceptive APIs, with the goal of substantially decreasing the cost of production and so enabling their use in developing nations. This present work combines the selection and engineering of a carbonyl reductase (CRED) enzyme from Almac's selectAZyme™ panel, with process development, to enable efficient and economically viable bioreduction of ethyl secodione to (13R,17S)-secol, the key chirality introducing intermediate en route to etonogestrel and levonorgestrel API. CRED library screening returned a good hit with an Almac CRED from Bacillus weidmannii, which allowed for highly stereoselective bioreduction at low enzyme loading of less than 1% w/w under screening assay conditions. However, the only co-solvent tolerated was DMSO up to ∼30% v/v, and it was impossible to achieve reaction completion with any enzyme loading at substrate titres of 20 g L-1 and above, due to the insolubility of the secodione. This triggered a rapid enzyme engineering program fully based on computational mutant selection. A small panel of 93 CRED mutants was rationally designed to increase the catalytic activity as well as thermal and solvent stability. The best mutant, Mutant-75, enabled a reaction at 45 °C to go to completion at 90 g L-1 substrate titre in a buffer/DMSO/heptane reaction medium fed over 6 h with substrate DMSO stock solution, with a low enzyme loading of 3.5% w/w wrt substrate. In screening assay conditions, Mutant-75 also showed a 2.2-fold activity increase. Our paper shows which computations and rational decisions enabled this outcome.

Supramolecular Ionic Liquid Gels for Enzyme Entrapment.

Reported herein is an entrapment method for enzyme immobilization that does not require the formation of new covalent bonds. Ionic liquid supramolecular gels are formed containing enzymes that can be shaped into gel beads and act as recyclable immobilized biocatalysts. The gel was formed from two components, a hydrophobic phosphonium ionic liquid and a low molecular weight gelator derived from the amino acid phenylalanine. Gel-entrapped lipase from Aneurinibacillus thermoaerophilus was recycled for 10 runs over 3 days without loss of activity and retained activity for at least 150 days. The procedure does not form covalent bonds upon gel formation, which is supramolecular, and no bonds are formed between the enzyme and the solid support.

Transaminases for industrial biocatalysis: novel enzyme discovery.

Transaminases (TAms) are important enzymes for the production of chiral amines for the pharmaceutical and fine chemical industries. Novel TAms for use in these industries have been discovered using a range of approaches, including activity-guided methods and homologous sequence searches from cultured microorganisms to searches using key motifs and metagenomic mining of environmental DNA libraries. This mini-review focuses on the methods used for TAm discovery over the past two decades, analyzing the changing trends in the field and highlighting the advantages and drawbacks of the respective approaches used. This review will also discuss the role of protein engineering in the development of novel TAms and explore possible directions for future TAm discovery for application in industrial biocatalysis. KEY POINTS: • The past two decades of TAm enzyme discovery approaches are explored. • TAm sequences are phylogenetically analyzed and compared to other discovery methods. • Benefits and drawbacks of discovery approaches for novel biocatalysts are discussed. • The role of protein engineering and future discovery directions is highlighted.

Application of ω-Transaminases in the Pharmaceutical Industry.

Chiral amines are valuable building blocks for the pharmaceutical industry. ω-TAms have emerged as an exciting option for their synthesis, offering a potential "green alternative" to overcome the drawbacks associated with conventional chemical methods. In this review, we explore the application of ω-TAms for pharmaceutical production. We discuss the diverse array of reactions available involving ω-TAms and process considerations of their use in both kinetic resolution and asymmetric synthesis. With the aid of specific drug intermediates and APIs, we chart the development of ω-TAms using protein engineering and their contribution to elegant one-pot cascades with other enzymes, including carbonyl reductases (CREDs), hydrolases and monoamine oxidases (MAOs), providing a comprehensive overview of their uses, beginning with initial applications through to the present day.

ICT-based health information services for elderly people: past experiences, current trends, and future strategies.

Although health information is readily available on the Internet and has changed the way people deal with their health in many ways, the retrieval of relevant information remains problematic, especially for elderly people. With a focus on elderly people, this paper summarizes current trends in consumer health informatics, discusses past and present initiatives providing health-information services, and proposes a future strategy for the design of sustainable services. A systematic literature review and a review of past German and EU projects concerned with health information services for elderly people are given. Many publications focus on health information services for specific diseases and on their quality and semantic accessibility, yet few deal with presenting and customizing health information for elderly and disabled people. Past experiences from Germany suggest that very often the specific needs of this target group are not met, and therefore accessibility remains largely hypothetical. We propose a strategy with five key points for the design of sustainable health-information services for elderly people. More research is needed to customize web-based health information services to the needs of the user group that needs them most urgently - elderly and disabled people.

Novel ruthenium-based metathesis catalysts containing electron-withdrawing ligands: synthesis, immobilization, and reactivity.

The syntheses and reactivity of seven different ruthenium-based metathesis catalysts are described. Ru(CF3COO)2(PCy3)(=CH-2-(2-PrO)C6H4) (1), Ru(CF3COO)2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) (2), and Ru(CF3COO)2(PCy(3))(1,3-dimesityldihydroimidazolin-2-ylidene)(=CHC6H5) (3) were prepared via chlorine exchange by reacting RuCl2(PCy3)2(=CH-2-(2-PrO)C6H4), RuCl2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4), and RuCl2(PCy3)(1,3-dimesityldihydroimidazolin-2-ylidene)(=CHC6H5), respectively, with silver trifluoroacetate (Cy =cyclohexyl). In analogy, Ru(CF3CF2COO)2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) (4) and Ru(CF3CF2CF2COO)2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) (5) were prepared from RuCl2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) via reaction with CF3CF2COOAg and CF3CF2CF2COOAg, respectively. Ru(C6F5COO)2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) (6) and Ru(C6F5O)2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) (7) were prepared from RuCl2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) via reaction with C6F5COOTl and C6F5OTl, respectively. Supported catalysts Ru(PS-DVB-CH2OOCCF2CF2CF2COO)(CF3COO)(PCy3)(1,3-dimesityldihydroimidazolin-2-ylidene)(=CHC6H5) (8), Ru(PS-DVB-CH2OOCCF2CF2CF2COO)(CF3COO)(PCy3)(=CH-2-(2-PrO)C6H4) (9), and Ru(PS-DVB-CH2OOCCF2CF2CF2COO)(CF3COO)(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4) (10) were synthesized by reaction of RuCl2(PCy3)(1,3-dimesityldihydroimidazolin-2-ylidene)(=CHC6H5), RuCl2(PCy3)(=CH-2-(2-PrO)C6H4), and RuCl2(1,3-dimesityldihydroimidazolin-2-ylidene)(=CH-2-(2-PrO)C6H4), respectively, with a perfluoroglutaric acid-derivatized poly(styrene-co-divinylbenzene) (PS-DVB) support (silver form). Halogen exchange in PCy3-containing systems had to be carried out in dichloromethane in order to suppress precipitation of AgCl.PCy3. The reactivity of all new catalysts in ring-closing metathesis (RCM) of hindered electron-rich and -poor substrates, respectively, at elevated temperature (45 degrees C) was compared with that of existing systems. Diethyl diallylmalonate (DEDAM, 11), diethyl allyl(2-methylallyl)malonate (12), N,N-diallyl-p-toluenesulfonamide (13), N-benzyl-N-but-1-en-4-ylbut-2-enecarboxylic amide (14), and N-allyl-N-(1-carboxymethyl)but-3-en-1-yl-p-toluenesulfonamide (15) were used as educts. Supported catalysts were prepared with high loadings (2.4, 22.1, and 160 mg of catalyst/g PS-DVB for 8, 9, and 10, respectively). Catalyst 8 showed higher and catalysts 9 and 10 sowed significantly reduced activities in RCM compared to their homogeneous analogues. Thus, with 8, turnover numbers (TONs) up to 4200 were realized in stirred-batch (carousel) RCM experiments. To elucidate the nature of the bound species, catalysts 8-10 were subjected to 13C- and 31P-MAS NMR spectroscopy. These investigations provided evidence for the proposed structures. Leaching of ruthenium into the reaction mixture was low, resulting in ruthenium contents <85 ppb (ng/g) in the final RCM-derived products.

Synthesis of cis-fused carbo-bicycles by domino enyne cross-metathesis/intramolecular Diels-Alder Reaction.

A sequential combination of Ru-catalyzed enyne cross-metathesis (EYCM) and intramolecular Diels-Alder reaction (IMDA) is described. Different terminal alkynes and alpha,omega-dienes obtained by a Baylis-Hillman reaction were transformed into substituted cis-hexahydro-1H-indenes and cis-hexahydro-2H-naphthalin-1-ones.